Revolutionize Your Glucolipotoxicity-Mediated T2D Research

Open new avenue using a unique clinically relevant cell model. GLTx EndoC-βH5® is a new human pancreatic beta cell line that has been specifically designed to recapitulate pathological glucolipotoxicity-induced dysfunction as observed in Type 2 Diabetes patients.

GLTx EndoC-βH5® cell line offers you:

• Robustness: A stable model from early to pre-clinical stages of your drug discovery and development process
• Clinical relevance: GLTx EndoC-βH5® robustly replicate beta cell dysfunction and death induced by high glucose and free fatty acid aggression
• Immediate availability: Order now and start your assay without delay
• No time wasting: A ready-to-use model; thaw and implement your assay at D+2